Rxivist logo

Structural basis of a public antibody response to SARS-CoV-2

By Meng Yuan, Hejun Liu, Nicholas C. Wu, Chang-Chun D. Lee, Xueyong Zhu, Fangzhu Zhao, Deli Huang, Wenli Yu, Yuanzi Hua, Henry Tien, Thomas F Rogers, Elise Landais, Devin Sok, Joseph G Jardine, Dennis R. Burton, Ian A. Wilson

Posted 09 Jun 2020
bioRxiv DOI: 10.1101/2020.06.08.141267 (published DOI: 10.1126/science.abd2321)

Molecular-level understanding of human neutralizing antibody responses to SARS-CoV-2 could accelerate vaccine design and facilitate drug discovery. We analyzed 294 SARS-CoV-2 antibodies and found that IGHV3-53 is the most frequently used IGHV gene for targeting the receptor binding domain (RBD) of the spike (S) protein. We determined crystal structures of two IGHV3-53 neutralizing antibodies +/- Fab CR3022 ranging from 2.33- to 3.11-angstrom resolution. The germline-encoded residues of IGHV3-53 dominate binding to the ACE2 binding site epitope with no overlap with the CR3022 epitope. Moreover, IGHV3-53 is used in combination with a very short CDR H3 and different light chains. Overall, IGHV3-53 represents a versatile public VH in neutralizing SARS-CoV-2 antibodies, where their specific germline features and minimal affinity maturation provide important insights for vaccine design and assessing outcomes. ### Competing Interest Statement The authors have declared no competing interest.

Download data

  • Downloaded 1,763 times
  • Download rankings, all-time:
    • Site-wide: 7,301 out of 118,977
    • In microbiology: 386 out of 9,394
  • Year to date:
    • Site-wide: 3,108 out of 118,977
  • Since beginning of last month:
    • Site-wide: 15,060 out of 118,977

Altmetric data


Downloads over time

Distribution of downloads per paper, site-wide


PanLingua

Sign up for the Rxivist weekly newsletter! (Click here for more details.)


News